CORDIS
Résultats de la recherche de l’UE

CORDIS

Français FR

Biomarkers of renal graft injuries in kidney allograft recipients

Objectif

In renal allograft recipients, 10-year graft survival has not improved over the past decades. Histological examination of graft biopsies has long been the gold standard to confirm graft injuries, but biopsies are invasive and histological grading is not very robust. There is thus a need for robust, non-invasive methods to predict and diagnose acute and chronic graft lesions, to improve patient treatment, quality of life and long-term graft survival. Also, there is an unmet need for better understanding of the immune and non-immune mechanisms of interstitial fibrosis /tubular atrophy and graft loss.
Combining all the skills required to build upon previous findings, BIOMARGIN will offer such opportunities in renal transplantation by integrating several omics approaches (mRNA, miRNA, peptides, proteins, lipids and metabolites) in blood, graft tissue and urine, in a well thought out, multistage discovery-to-validation translational programme, following the highest European ethics and regulatory requirements, as well as quality controls and quality assessments at all clinical and analytical steps. It is probably one of the first programmes to pursue such an integrated and systematic research approach.
BIOMARGIN aims to: (i) discover, select and validate blood and/or urine biomarkers of renal allograft lesions in adult and pediatric kidney transplant recipients; (ii) provide renal transplant physicians with non-invasive, robust diagnostic tests and interpretation algorithms enabling closer, more accurate, more predictive and/or less invasive monitoring of transplanted patients; (iii) help to avoid or diminish the use of biopsies and improve patient treatment, quality of life and long-term graft survival; (iv) help understand the mechanisms involved in the allograft injury processes which, combined with mass spectrometry imaging should offer pathologists new molecular targets and tools for renal graft biopsy analysis.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinateur

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

Adresse

Rue De Tolbiac 101
75654 Paris

France

Type d’activité

Research Organisations

Contribution de l’UE

€ 1 509 502

Contact administratif

Muriel Bouas (Ms.)

Participants (12)

Trier par ordre alphabétique

Trier par contribution de l’UE

Tout développer

INSERM TRANSFERT SA

France

Contribution de l’UE

€ 455 400

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

France

Contribution de l’UE

€ 305 820

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

France

Contribution de l’UE

€ 455 576

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

Contribution de l’UE

€ 201 358

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgique

Contribution de l’UE

€ 748 000

VLAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK N.V.

Belgique

Contribution de l’UE

€ 273 016

MOSAIQUES DIAGNOSTICS GMBH

Allemagne

Contribution de l’UE

€ 256 259

MEDIZINISCHE HOCHSCHULE HANNOVER

Allemagne

Contribution de l’UE

€ 306 407

Cardinal Systems

France

Contribution de l’UE

€ 627 462

UNIVERSITE PARIS DESCARTES

France

Contribution de l’UE

€ 309 000

AcureOmics AB

Suède

Contribution de l’UE

€ 311 000

Centre hospitalier universitaire de Limoges

France

Contribution de l’UE

€ 241 200

Informations projet

N° de convention de subvention: 305499

État

Projet clôturé

  • Date de début

    1 Mars 2013

  • Date de fin

    28 Février 2018

Financé au titre de:

FP7-HEALTH

  • Budget total:

    € 7 836 208

  • Contribution de l’UE

    € 6 000 000

Coordonné par:

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France